Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aristotle University Of Thessaloniki
Age
50–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Males and females \>50 years old with:
Primary Open-Angle Glaucoma newly diagnosed or with anti-glaucoma medical treatment \< =12 weeks
Pseudoexfoliative Glaucoma newly diagnosed or with anti-glaucoma medical treatment \<= 12 weeks
Ocular Hypertensives newly diagnosed or with anti-glaucoma medical treatment \<= 12 weeks
Age-matched controls
IOP\>=22mmHg at the eligibility visit for glaucoma patients and ocular hypertensives
You may not be if
For Eye
Use of any ophthalmic medication (drops) during the study (except for natural tears)
Inflammation of any aetiology
Previous eye surgery or laser
Corneal abnormalities (oedema, dystrophies etc) For Subjects
Systemic diseases which affect the cornea (such as autoimmune diseases)
Inability to participate due to advanced age or serious illness
Mean IOP\>36mmHg in either eye at the eligibility visit.
Subjects who cannot safety discontinue use of all IOP-lowering medication(s) for washout
Subjects with severe central visual field loss in either eye. Severe central visual field loss is defined as sensitivity \<=10dB in at least 2 of the 4 visual field test points closest to the point of fixation
Other types of glaucoma (such as angle-closure glaucoma and secondary glaucomas)
Clareo Health | Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure
